Impact of awake prone positioning duration on intubation or mortality in COVID-19 patients with acute respiratory failure: secondary analysis of a randomized clinical trial.

Summary

In a secondary analysis of a multicenter RCT dataset (n=408) in COVID-19 AHRF, longer daily awake prone positioning was linked to lower risk of intubation or death, with benefit concentrated in the first 3 days. A nonlinear association identified 8–12 hours/day as optimal; <8 hours increased risk, whereas >12 hours conferred no added benefit.

Key Findings

• Longer daily APP duration was associated with reduced risk of intubation or death (HR 0.93 per hour; 95% CI 0.88–0.98).
• The protective association was significant only during the first 3 days after randomization.
• A nonlinear relationship indicated an optimal APP duration of 8–12 h/day; <8 h increased risk (HR 2.44), >12 h offered no additional benefit (HR 1.03).

Clinical Implications

Implement APP protocols that aim for 8–12 hours/day, especially during the first 72 hours, and track adherence; extending beyond 12 hours is unlikely to add benefit and may increase burden.

Limitations

• Secondary analysis with non-randomized exposure to APP duration introduces potential residual confounding (e.g., tolerance/severity).
• Limited to COVID-19 AHRF; generalizability to non-COVID ARDS remains uncertain.

Future Directions

Pragmatic trials or adaptive protocols prescribing 8–12 h/day APP targets; test applicability in non-COVID ARDS and evaluate patient-centered outcomes and safety.